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Abstract
The Caudal-related homeobox genes Cdx1 and Cdx2 are intestine-specific transcription factors that regulate differ-
entiation of intestinal cell types. Previously, we have shown Cdx1 to be antiproliferative and to promote cell differ-
entiation. However, other studies have suggested that Cdx1 may be an oncogene. To test for oncogenic behavior,
we used the murine villin promoter to ectopically express Cdx1 in the small intestinal villi and colonic surface ep-
ithelium. No changes in intestinal architecture, cell differentiation, or lineage selection were observed with expres-
sion of the transgene. Classic oncogenes enhance proliferation and induce tumors when ectopically expressed.
However, the Cdx1 transgene neither altered intestinal proliferation nor induced spontaneous intestinal tumors. In
a murine model for colitis-associated cancer, the Cdx1 transgene decreased, rather than increased, the number of
adenomas that developed. In the polyps, the expression of the endogenous and the transgenic Cdx1 proteins was
largely absent, whereas endogenous Villin expression was retained. This suggests that transgene silencing was spe-
cific and not due to a general Villin inactivation. In conclusion, neither the ectopic expression of Cdx1 was associated
with changes in intestinal cell proliferation or differentiation nor was there increased intestinal cancer susceptibility.
Our results therefore suggest that Cdx1 is not an oncogene in normal intestinal epithelium.
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Introduction
The continuous renewal of intestinal epithelium provides many
unique challenges. Rates of cell production must be precisely bal-
anced by cell loss or destruction, otherwise the epithelial barrier func-
tion is compromised, or, alternatively, tumors and obstructing masses
form, obliterating the normal lumen. Cell proliferation and differen-
tiation are thus tightly controlled in the normal intestinal epithelium.
Our current understanding of these processes is limited but improv-
ing. Many of the transcription and growth factors that regulate intes-
tinal cell proliferation or differentiation have been identified [1–6].
The Caudal-related homeobox (Cdx) transcription factors play key
roles in regulating intestinal epithelial differentiation and prolifera-
tion [7,8]. The Cdx homologues modulate a diverse set of processes
including proliferation, apoptosis, cell adhesion, and the acquisition
of a columnar morphology [7]. They are also necessary for the ex-
pression of an increasing number of intestine-specific genes [9–13].
Abbreviations: AOM, azoxymethane; BrdU, bromodeoxyuridine; CDX1, CDX2 = human
genes; Cdx1, Cdx2 = mouse genes or species not specified; DSS, dextran sodium sulfate;
RT-PCR, reverse transcription–polymerase chain reaction; SI, sucrase isomaltase; TCF,
T cell factor
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By targeting these various processes and genes, the Cdx homologues
contribute toward the maintenance of this balance between prolifera-
tion and differentiation.
Numerous studies have sought to define the role of the Cdx homo-
logues in human colon carcinogenesis. Unfortunately, the question as
to whether these transcription factors hinder or contribute to the pro-
cess of carcinogenesis remains unsettled. Cdx2, the more intensively
studied of the two, was historically thought of as a tumor suppressor
[14,15], although recent studies have suggested that it may have on-
cogenic potential [16–18].
In contrast to Cdx2, little is known about Cdx1’s role. Historically,
Cdx1 was described as an oncogene due in part to reports that it pro-
moted proliferation of IEC6 and Caco-2 cells [19,20]. Moreover,
Wnt/β-catenin signaling is required for Cdx1 expression [21], sug-
gesting that Cdx1 may promote Wnt-mediated proliferation. How-
ever, we have reported that restoring Cdx1 expression to colon cancer
cells inhibited proliferation by blocking β-catenin/T cell factor tran-
scriptional activity [22]. Thus, in our model, Cdx1 could negatively
feedback on the Wnt/β-catenin signaling pathway to limit cell pro-
liferation. The data from human colon cancer specimens do not
completely clarify the issue. In the majority of human colon cancer
specimens studied, CDX1 expression is lost due to active CDX1 gene
silencing by promoter hypermethylation [23–25]. However, a subset
of colon cancers may express increased levels of Cdx1 mRNA and
protein [26,27].
Therefore, to directly test what the effects of Cdx1 overexpression
are on intestinal oncogenesis, we generated transgenic mice with ec-
topic and overexpression of Cdx1 in the small intestinal and colonic
epithelium using the murine Villin promoter. This expression did
not alter endogenous Cdx1 mRNA levels, but there was a reciprocal
reduction in Cdx2 mRNA and protein levels. The transgene had no
effect on intestinal cell proliferation rates or differentiation of the
four cell lineages. We observed the mice for up to 24 months and
did not observe the development of any spontaneous intestinal
polyps or cancers. Moreover, in a mouse model of inflammation-
associated neoplasia, we found that the ectopic Cdx1 expression re-
duced neoplasia formation by nearly 50%. In addition, we noted the
reduction of endogenous and absence of transgenic Cdx1 expression
in the polyps that did form, whereas endogenous Villin expression
remained robust. This suggests that loss of the Cdx1 transgene ex-
pression was a specific event and not simply due to a general loss
of Villin gene expression. We conclude that ectopic overexpression
of Cdx1 in normal intestinal epithelium does not have an oncogenic
effect but may instead have significant antitumorigenic properties.
Materials and Methods
Transgenic Construct
To add a cMyc-tag to Cdx1, a full-length mouse Cdx1 cDNA
was liberated from pRC-Cdx1 [28] and ligated into pCMV-Tag3c
(Stratagene, La Jolla, CA). Then this cMyc-tagged Cdx1 cDNA,
along with the SV40 polyA, were subcloned from pCMV-Tag3c into
pBluescript KS to generate pCdx1-KS. The 12.4-kb mouse Villin pro-
moter [29] was also subcloned into pBluescript to generate pVillin-
KS. Then the cMyc-tag-Cdx1-SV40 polyA cassette was ligated into
pVillin-KS to generate the final Villin-myc Cdx1 construct. TOPFLASH
reporter was kindly provided by Ken Kinzler (Johns Hopkins University,
Baltimore, MD).
Generation of Villin–Cdx1 Transgenic Mice
All animal experiments were performed under an animal use pro-
tocol approved by the University of Pennsylvania IACUC Commit-
tee. The final Villin-myc Cdx1 DNA construct was linearized and
injected into the male pronuclei of fertilized eggs and implanted into
pseudopregnant females by the Transgenic and Chimeric Mouse Core
Facility at the University of Pennsylvania. Founder animals were iden-
tified by polymerase chain reaction (PCR) amplification of tail DNA
with genotyping primers and confirmed by Southern blot with a villin
intron probe [29]. Three founders were obtained from two separate
injections. Transgene founders of the BGSJL/F1 strain (Jackson Lab-
oratory, Bar Harbor, ME) were bred with normal CD-1 mice (Charles
River, Wilmington, MA), and offspring were analyzed for the trans-
gene by PCR. Therefore, mice used in these studies were on a mixed
genetic background. There were no significant phenotypic differences
between the three lines. The reported figures are therefore the com-
bined results of the three lines.
Immunohistochemistry
Intestinal regions were isolated, rinsed in ice-cold PBS, fixed, and
embedded as described [30]. Primary antibodies used include Cdx1
CPSP [30], bromodeoxyuridine (BrdU) (Upstate, Charlottesville,
VA), monoclonal Cdx2 (Biogenex, San Ramon, CA), sucrase iso-
maltase (SI) (gift of K. Yeh, Louisiana State University, Shreveport,
LA), α-chromagranin (Immunostar, Hudson, WI), lysozyme (Dako,
Carpinteria, CA), and human cMyc-tag (BDPharmingen, San Jose, CA).
The primary antibodies were visualized using a biotinylated secondary
antibody and an avidin–horseradish peroxidase conjugate (Vectastain
ABC kit; Vector Laboratories, Burlingame, CA). The slides were de-
veloped with DAB (Vector Laboratories). For Alcian blue staining,
slides were deparaffinized. After application of 3% aqueous acetic acid
to the slides, 1% Alcian blue in 3% acetic acid, pH 2.5, was applied.
Sections were washed and counterstained with 0.1% nuclear fast red,
dehydrated, and mounted. Alkaline phosphatase activity was analyzed
by deparaffinization of slides followed by incubation with 5-bromo-4-
chloro-3-indolyl-phosphatase-4-nitro blue tetrazolium chloride. Crypt
depth and villi length weremeasured in the ileum of transgenic and non-
transgenic littermate controls using a software (IPLab; Scanalytics, Fair-
fax, VA). At least 10 crypts and 10 villi were measured in each mouse.
Three transgenic and three littermate control mice were measured from
each transgenic line for this study.
Western Blot Analysis
Nuclear proteins were isolated from the intestinal epithelium of
adult mice by an adaptation of a previously described method [9].
Western blot analysis was then conducted. The blot was incubated
with rabbit polyclonal Cdx1 antibody and then visualized with sec-
ondary antibodies and electrochemiluminescence detection (ECL
Plus kit; Bio-Rad). To verify equal loading of samples, the blots were
stripped and reprobed with anti-YY1 (Santa Cruz Biotechnology,
Santa Cruz, CA) at 1:500.
RNA Detection By Quantitative Reverse
Transcription–Polymerase Chain Reaction
Sections of the distal jejunum were stored in a nontoxic tissue storage
reagent (RNAlater; Ambion, Austin, TX). Total RNAwas isolated from
the tissue with a RNeasy Midi kit (Qiagen, Valencia, CA). cDNA was
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prepared from 1 μg of total RNA using Superscript II (Invitrogen,
Carlsbad, CA) and random hexamers.
Primers for regular reverse transcription–polymerase chain reaction
(RT-PCR) detection of total Cdx1:
FCdx1 468 5′ GCGCCTACGAATGGATG 3′
RCdx1 613 5′ TCTTTACCTGCCGCTCTGTGAG 3′ (spans
intron 1)
Transgene-specific RNA primers:
FCdx1 665 5′ CGGCAGGTAAAGATCTGGTTC 3′ (crosses exon
2/3 boundary)
RSV40 5′ GAGCCTTGGGACTGTGAATCT 3′
Quantitative RT-PCR was performed on a detection system (ABI
7000; Applied Biosystems, Foster City, CA), with SYBR green used
as the fluorescent dye. Primers were designed using Primer Express
software (Applied Biosystems).
Cdx1 primers that recognize both the transgene and the endogenous
Cdx1
5′ AGACCGAACCAAGGACAAG 3′
5′ TGATGTACCGGCTGTAGTGAA 3′
Specific primers that only recognize endogenous Cdx1
qFCdx1UTR CTAGGACAAGTAGCTTGCCCTCTT 3′
qRCdx1UTR 5′ TCCAACAGGCTCACCACACA 3′
Specific primers that only recognize endogenous Cdx2
5′ CGATACATCACCATCAGGAGG 3′
5′ TGGCTCTGCCGGTTCTGAAA 3′
Transgene-specific quantitative PCR primers
FVMCex1 5′ TGGCTGCCTCTTCCAGACA 3′
qRCdx1ex1 5′ CCACGTAGGGCTTCAGATCC 3′.
Standard PCR conditions were as then used. A dissociation curve was
run with each PCR to ensure that primer–dimer formation did not oc-
cur. PCR results were analyzed using the ΔΔCt analysis (User Bulletin 2,
Applied Biosystems), with 36B4 used as the housekeeping gene.
Proliferation Studies
Mice were injected with BrdU (Zymed) 1 hour before sacrifice.
After BrdU immunohistochemistry, BrdU-labeled nuclei were
counted in 15 full-length crypts that touched the basement mem-
branes from regions of the small intestine and colon. Positive cells
were expressed as the number of BrdU(+) cells per crypt unit. Three
transgenic and matched nontransgenic littermates from each of the
three Villin–Cdx1 lines were used in this study.
Azoxymethane/Dextran Sodium Sulfate Studies
Animals were injected with a single 10 mg/kg dose of azoxymethane
(AOM) (Sigma, St. Louis, MO) at 6 weeks of age. One week later,
animals received 3% dextran sodium sulfate (DSS) (MP Biochemicals,
Solon, OH) in their drinking water for 7 days. After 14 days on regular
water, the treated animals received a second round of DSS. A subgroup
of these mice received a third round. Control animals received AOM
alone, or DSS alone, at the same time as the test groups. Animals were
euthanized at 14 weeks after the AOM injection. The colons were
opened longitudinally, stained with 1% methylene blue, and examined
under a dissecting microscope and scored for polyps. The tissue was
then fixed and sections with polyps were subdivided for microscopic
analysis. Polyps were independently examined by two blinded investi-
gators who scored them as adenoma, lymphoid aggregate, or normal
colon. A board-certified pathologist blinded to the treatment scored
each adenoma for its degree of dysplasia. Polyp diameter was measured
using IPLab software (Scanalytics) and recorded during the histologic
examination of the polyps. Student’s t test was performed to compare
findings in the AOM/DSS–treated transgenic mice with the AOM/
DSS–treated controls. After these parameters were recorded, some
polyps had additional sections immunohistochemically stained for
Cdx1, the cMyc-tag, and Cdx2 as before.
Results
Development of a Transgenic Mouse Line Ectopically
Expressing Cdx1 throughout the Mouse Intestine
Transgenic mice were generated containing a construct with 12.4 kb
mouse villin regulatory sequences (kindly provided by Dr. Deborah
Gumucio, University of Michigan) driving expression of mouse
Cdx1 cDNA (Figure 1A). An N-terminal cMyc-tag was added to dif-
ferentiate transgenic from endogenous Cdx1. Before generating the
transgenic mice, the villin–mycCdx1 construct was tested to con-
firm expression of active Cdx1 protein. The mycCdx1 protein was ex-
pressed and localized to the nucleus when the villin–mycCdx1
construct was transfected into Caco-2 cells (Figure 1B). In addition,
we demonstrate that this construct can induce transcriptional activity
from a canonical Cdx-responsive promoter, SI, when they are cotrans-
fected into 293T cells. Lastly, the mycCdx1 protein can inhibit
β-catenin/TCF transcriptional activity in 293T cells, as demonstrated
by the suppression of TOPFLASH reporter activity (Figure 1C ). Both
results are consistent with wild-type Cdx1 activity, as previously pub-
lished [22].
Three distinct transgenic lines were established and studied using
the villin–mycCdx1 construct. All three lines were viable and yielded
transgenic pups in the expected Mendelian ratios. Transgenic pups ap-
peared healthy and grew at rates similar to their wild-type littermates,
with indistinguishable weight gains (data not shown). All three lines
expressed the transgene mRNA and protein (Figure 1, D and E,
and data not shown). Levels of transgenic protein expression appeared
similar in the three lines, and transgenic Cdx1 levels were uniformly
much higher than that of Cdx1 in wild-type littermates.
Transgene expression was detected at 1 month of life and was
maintained in the animal for at least 12 months for all three founders
studied (Figure 2). Expression earlier than 1 month was not evaluated
for this study, but others have reported expression as early as em-
bryonic day 15 (E15) when using this promoter as a transgene
[29]. We have in fact studied several animals as old as 24 months,
and transgene expression was still maintained (data not shown). Ex-
pression of the transgene Cdx1 protein, rather than enhancement of
endogenous Cdx1 gene expression, was further confirmed by the
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detection of cMyc-tagged nuclear protein expression in the villus epi-
thelial cells of the small intestine (Figure 2A). In summary, the 12.4 kb
mouse villin regulatory sequences successfully directed high levels of
Cdx1 transgene expression to the villi and superficial epithelium of
the small intestine and colon in three lines of transgenic mice.
Ectopic Cdx1 Expression Does Not Alter Intestinal Epithelial
Architecture, Cell Differentiation, or Cell Lineage Decisions
The villin–Cdx1 transgene directs ectopic Cdx1 expression to the villi
and surface epithelium of the small intestine and colon (Figure 2).
Transgene expression was somewhat variable in the duodenum and
highest in the ileum. Colonic expression was maintained throughout
the colon to the rectum. Ectopic Cdx1 expression did not appear
to alter the architecture of the crypts and villi of the small intestine
and colon at 1 month or 12 months of age (Figure 2). Crypt depth
and villus length were no different in the villin–Cdx1 mice (100 ±
26 and 240 ± 25 μM, respectively) when compared to nontransgenic
littermate controls (109 ± 26 and 230 ± 35 μM, respectively).
Cell differentiation in the intestinal epithelium is assessed by cell
shape and morphology, cell lineage determination (absorptive enter-
ocyte, goblet cell, enteroendocrine cell, or paneth cell), as well as
the expression of markers for terminal differentiation. We stained
small intestinal tissue for two enzymes associated with intestinal dif-
ferentiation, SI, and alkaline phosphatase. The expression levels of
both enzymes are regulated in part by the transcriptional activity
Figure 1. Development of a transgenic mouse line ectopically expressing Cdx1 throughout the mouse intestine. (A) Mouse Cdx1 cDNA
was cloned into pCMV-Tag3C to add an N-terminal human cMyc tag and SV40 PolyA, then placed behind 12.4 kb of mouse villin gene
regulatory sequences, which included the promoter, untranslated exon 1, intron 1, and the start of exon 2. Genotyping primers, indi-
cated by black arrows, amplified the junction of villin and Cdx1. RT-PCR primers, represented by gray arrows, amplified the junction of
Cdx1 and SV40 PolyA. An N-terminal cMyc tag was added to differentiate transgenic from endogenous Cdx1. (B) The villin–mycCdx1
transgene expresses a functioning Cdx1 protein. mycCdx1 protein is detected in nuclear extracts from cells after transfection and
is detected in the nucleus by immunofluorescence using anti-Cdx1 or anti-myc antibodies. Equal protein loading was confirmed by
YY1 immunoblot analysis. VE, Villin-empty; VMC, Villin–mycCDX1. (C) Transient transfection of mycCdx1 into 293T induces luciferase
activity from a canonical Cdx reporter, SI. Gray bar, empty vector control;white bar, mycCdx1. Cotransfection of the canonical β-catenin/
TCF reporter TOPFLASH with mycCdx1 constructs demonstrates that the chimera can inhibit β-catenin/TCF transcriptional activity.
Black bar, empty vector alone; gray bar, empty vector with β-catenin expression vector; white bar, mycCdx1 with β-catenin expression
vector. (D) Transgene expression is shown by RT-PCR. RNA was isolated from the distal jejunum and colon of 1-month-old offspring
from two different founders. RT-PCR with Cdx1/SV40 primers demonstrated expression of the transgene in both the small intestine
and colon. (E) Overexpression of Cdx1 in the intestine in the Villin–Cdx1 transgenic mice. Jejunum tissue from offspring of two dif-
ferent founders. Nuclear extracts were isolated and loaded on sodium dodecyl sulfate–polyacrylamide gels. Western blot with Cdx1
antibody demonstrates overexpression of Cdx1 in transgenic animals. The same blot was stripped and reprobed with an antibody to
nuclear protein YY1 to demonstrate even loading. F3138 and F3139 are the designations of the founder line serving as the source of the
jejunal tissue.
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of Cdx1 or Cdx2. Whereas SI expression is believed to require Cdx2
transcriptional activity for its expression, alkaline phosphatase expres-
sion is inhibited by Cdx2 and enhanced by Cdx1 [9,31]. The pattern
of SI expression appeared to be unchanged in the villin–Cdx1 mice
compared to their littermate controls (Figure 3A). Extensive brush
border staining was detected in both the transgenic and the control
mice. In addition, robust alkaline phosphatase enzymatic activity was
similarly detected along the small intestine brush border surface of
Villin–Cdx1 and control mice. Together, these findings suggest that
ectopic Cdx1 expression in the villus epithelial cells did not hinder or
disrupt the normal patterns of intestinal epithelial cell differentiation.
We then examined for changes in the different lineages of our villin–
Cdx1 mice by staining for specific markers. Chromagranin A, a com-
ponent of secretory vesicles, has long been used as a general marker
for the enteroendocrine cell lineage. Similarly, the enzyme lysozyme,
a component of the paneth cell secretory granules, has been used to
identify paneth cells in the intestinal epithelium. We stained for these
markers in our villin–Cdx1 and control mice and found no significant
differences in the numbers of paneth and enteroendocrine cells (Fig-
ure 3B). Alcian blue avidly stains intestinal mucins present in goblet
cells. Alcian blue staining suggested that there might be a small increase
in goblet cell numbers in our villin–Cdx1 mice. However, formal
counting of Alcian blue–stained cells found only a small, statistically
insignificant increase in ileal goblet cell numbers in two of the transgenic
lines (Figure 3C and data not shown). In summary, ectopic expression
of Cdx1 in the murine small intestine did not alter epithelial cell mor-
phology, differentiation, or cell lineage selection.
Expression of the Homologue Cdx2 Is Diminished By
Ectopic Cdx1 Expression in Transgenic Mice
The Caudal homologue Cdx2 is a phosphoprotein that is ex-
pressed throughout the entire crypt–villus axis [7,32,33]. Its expres-
sion overlaps with Cdx1 in the crypts. In our transgenic mice, we
found that Cdx2 staining was considerably reduced in both the small
intestine and the colon in the regions where the Cdx1 transgene is
expressed (Figure 4, A and B). This finding was somewhat unexpected,
as SI and alkaline phosphatase levels were not altered in the villin–
Cdx1 mice (Figure 2A). We confirmed the reduction in Cdx2 using
quantitative real-time SYBR green RT-PCR. Cdx2 RNA is decreased
two-fold in the villin–Cdx1 mouse small intestines when compared to
nontransgenic littermates (Figure 4C ).
We had previously demonstrated that Cdx1 expression could re-
duce the β-catenin–dependent activity of its own promoter [22].
To determine if transgenic Cdx1 altered the expression of the endog-
enous Cdx1 gene, we measured both total and endogenous Cdx1
mRNA levels using real-time quantitative RT-PCR. We used two
primer pairs, one that recognizes both the transgenic and endogenous
Cdx1 mRNA, and one primer pair specific for the endogenous Cdx1
Figure 2. Cdx1 ectopic expression in the small intestine villi and colon surface epithelium of Villin–Cdx1 transgenic mice. The small
intestine and colon from transgenic or littermate control mice were excised at 1 and 12 months, fixed overnight in 4% paraformalde-
hyde, then processed for immunohistochemical studies. (A) Anti-Cdx1 antibody (CPSP) demonstrating that Cdx1 protein is limited to the
crypt epithelial cells in 1-month-old wild-type mice (arrow). In contrast, in villin–Cdx1 transgenic mice, we see darkly stained nuclei in the
upper crypt and in the villus epithelial cells (arrowhead). A mouse monoclonal antibody against the human cMyc-tag does not recognize
endogenous mouse cMyc in the crypt cells of 1-month-old wild-type offspring (gray arrow) but detects nuclear-localized transgene ex-
pression in the small intestinal villi of transgenic mice (arrowhead). (B) These patterns of Cdx1 expression persist in 1-year-old wild-type
and transgenic animals. Cdx1 protein is limited to the colon crypts of 1-year-old wild-type mice but is highly expressed in the colon
surface epithelium of transgenic mice.
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gene transcript (Figure 1A). Total Cdx1 mRNA levels were increased
three- to five-fold in the small intestine of transgenic mice (Fig-
ure 4D). This increase was entirely due to the villin–Cdx1 transgene,
as mRNA levels from the endogenous Cdx1 gene were unchanged. In
summary, ectopic expression of Cdx1 induced a reciprocal reduction
in the expression of the Caudal homologue Cdx2 without affecting
epithelial cell differentiation.
Proliferation Rates in the Small Intestine and Colon Were
Not Altered By Ectopic Expression of Cdx1
In prior studies of colon cancer cells, we demonstrated that resto-
ration of Cdx1 expression significantly reduced rates of cell prolifer-
ation [34–36]. We therefore tested for changes in intestinal epithelial
proliferation in our transgenic villin–Cdx1 mice by measuring BrdU
labeling rates. As in nontransgenic controls, BrdU (US Biological,
Swampscott, MA) incorporation was localized to the crypt compartment
and appeared unaltered by ectopic Cdx1 expression (Figure 5A and data
not shown). When extensive cell counts were performed on 6-month-
old mice, no significant differences emerged in either the small intestine
or the colon (Figure 5B). A subgroup analysis with each of the transgenic
lines yielded similar findings (data not shown). We concluded that ec-
topic expression of Cdx1 by the murine villin promoter did not alter
intestinal epithelial or colonic rates of proliferation or its distribution
along the crypt–villus axis.
Ectopic Cdx1 Expression in the Surface Epithelium of the
Colon Did Not Cause or Accelerate Tumor Formation
One important question these transgenic mice are designed to ad-
dress was whether the Cdx1 transcription factor had oncogenic prop-
erties in intestinal epithelium. Gene products classically thought of as
oncogenes typically induce tumors when ectopically expressed or
overexpressed [37]. However, despite examining more than 150 mice
from each of the three lines, including ages 1 month to 24 months,
no intestinal tumors or polyps were observed in the transgenic mice
(data not shown). It therefore seems unlikely that Cdx1 is an intesti-
nal oncogene in the classic sense.
To further test for oncogenic potential of Cdx1, we investigated
whether the ectopic Cdx1 expression would increase rates of colonic
neoplasia in a mouse model for inducible colon cancer [38,39]. We
treated mice with AOM (10 mg/ml) and either two rounds or three
rounds of 3% DSS in their drinking water. As this treatment gener-
ally produces tumors in the rectum, we confirmed expression of our
Figure 3. No change in markers for enterocyte differentiation or cell lineages due to ectopic Cdx1 expression. (A) Immunohistochemistry
with anti–sucrase isomaltase antibody shows no change in pattern of sucrase isomaltase gene expression in the small intestine brush
border between 7-month-old wild-type and villin–Cdx1 transgenic mice. No difference in activity of brush border enzyme alkaline phos-
phatase noted in 7-month-old wild-type and transgenic mice. (C) Seven-month-old wild-type and villin–Cdx1 transgenic mice show no
difference in the distribution of immunohistochemical staining for an enteroendocrine cell marker (chromagranin-A) or a paneth cell
marker (lysozyme). (B) Similarly, staining with Alcian blue, a marker for goblet cells in the ileum of the small intestine and colon, was
unchanged by ectopic Cdx1 expression in wild-type and transgenic small intestine.
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transgene to the squamo-columnar border (Figure 6A). With these
doses of DSS, we obtained neoplastic polyps in all the mice included
in the study (Table 1). Polyps were located in the distal colon, and in
general, the nontransgenic mice appeared to have bulkier disease.
None of the control or transgenic mice treated with either AOM
or DSS alone developed histologically confirmed adenomas. Only
the combination of these agents elicited a true neoplastic response.
Villin–Cdx1 transgenic mice had about half as many neoplastic
polyps as their similarly treated nontransgenic littermates (5 vs 9.2;
P < .013) (Figure 6B). Mice treated with two rounds of 3% DSS
developed 3.5 adenomas/mouse compared to their nontransgenic
littermates who develop 8.3 neoplastic polyps on average (P <
.037) (Figure 6C ). Treatment of the mice with three rounds of
DSS led to an increase in the average number of polyps in all mice.
However, the villin–Cdx1 transgenic mice still had fewer adenomas
than controls (5.8 polyps/mouse vs 9.8 polyps/mouse; P < .038).
Other tumor parameters were compared in this study, including
polyp diameter, degree of dysplasia, and expression of Cdx1 and
Cdx2. A single carcinoma in situ was identified among the more than
200 polyps examined, and it developed in a villin–Cdx1 transgenic
Figure 4. Ectopic expression of Cdx1 reduces Cdx2 expression in the small intestine villi and colon surface epithelium. Immunohisto-
chemistry with either Cdx1 or Cdx2 antibodies on adjacent sections from 9-month-old nontransgenic and Villin–Cdx1 littermates. (A)
Small intestine of nontransgenic mice with normal Cdx1 and Cdx2 expressions. Arrow points to reduced Cdx2 staining. (B) Cdx1 and
Cdx2 expression pattern in the colon of transgenic and nontransgenic mice. Arrowhead points to reduced Cdx2 staining. (C) Real-time
RT-PCR quantification of Cdx2 mRNA levels in the small intestine of transgenic and nontransgenic littermates. (D) Endogenous Cdx1 and
total mRNA levels in the small intestine determined by quantitative RT-PCR.WT, wild-type; Tg, transgenic; NS, nonsignificant differences.
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mouse. The remaining polyps were all classified as adenomas, with ei-
ther low-grade or high-grade dysplasia. Despite the carcinoma, there
was no significant difference between the groups in degree of polyp
dysplasia (data not shown). The diameter of the adenomatous polyps
was quite variable, ranging from 0.30 to 7.9 mm in the villin–Cdx1
mice and from 0.34 to 8.2 mm in the control mice. Despite the great
variability in polyp sizes, there was a trend for smaller polyps in the
transgenic mice in both treatment groups. However, statistical signif-
icance was only achieved in the group receiving the three rounds of
DSS treatment (1.6 vs 2.1 mm; P = .019) (data not shown).
Immunohistochemical levels of Cdx1 and Cdx2 were significantly
diminished in all polyps tested. Nuclear Cdx1 staining was infre-
quently detected in the 10 transgenic and 10 nontransgenic polyps
studied (Figure 7A). Patchy Cdx2 expression persisted in many of the
polyps, but overall Cdx2 levels were reduced compared to adjacent
normal colon. Of interest, in the transgenic mice, the Myc-tag anti-
body failed to detect transgenic Cdx1 protein in the polyps, indicat-
ing a loss of villin–Cdx1 transgene expression.
In conjunction with the absence of transgene expression, we noted
elevated levels of nuclear β-catenin staining, and retention of villin
protein expression, although the villin protein does not localize to
the apical surface in adenomas as efficiently as it does in normal ep-
ithelial cells (Figure 7B). Thus the loss of villin–Cdx1 expression is
not due to a general loss of villin gene expression or that the neoplas-
tic polyp cells are in an undifferentiated state. Lastly, the distribution
of β-catenin protein in the normal intestine appeared unaltered by
the expression of the transgene. Together, these findings suggest that
the villin–Cdx1 transgene might limit tumorigenesis at an early stage,
possibly in the aberrant crypt foci, by inhibiting proliferation or neo-
plastic progression. Dysregulated Wnt/β-catenin signaling occurs fre-
quently in aberrant crypt foci and could be the target of the transgene
effect [40,41]. Determining the molecular mechanism for this inter-
esting observation is a focus for future studies.
We conclude that ectopic Cdx1 expression in the surface epithe-
lium of the colon does not increase cell proliferation nor induce tu-
mor formation or accelerate tumor growth. It does not behave as an
oncogene in the normal intestinal epithelium. Instead, it is able to
reduce polyp formation in a mouse model for colitis-associated can-
cer and may therefore act to suppress colon carcinogenesis.
Discussion
Cdx1 and Cdx2 Are Caudal Homologues with a Conserved
Structure and Overlapping Function
The Caudal-related homeodomain transcription factors Cdx1 and
Cdx2 are highly conserved. As Caudal homologues, they are highly
conserved structurally, with a high degree of homology throughout,
and they share a 90% amino acid identity in the all-important DNA
binding domain. This degree of structural conservation would sug-
gest that these homologues might share a number of important tran-
scriptional targets and thereby have shared functions. Indeed, this has
been borne out in at least one study, where it was established that
Cdx1 and Cdx2 have compensatory roles in anteroposterior pattern-
ing and posterior axis elongation [42]. Despite this shared structure
and function, Cdx1 and Cdx2 have long been thought of as having
opposing effects on proliferation and gene expression in the intestinal
epithelium. This is perhaps best evidenced by the fact that Cdx1 has
been called an oncogene by some investigators, whereas Cdx2 has
long been thought of as a tumor suppressor [12,14,15,20,27,31,43].
We have been interested in the role played by the Cdx factors in
normal intestinal cell proliferation and colon tumorigenesis. We
found that both Cdx1 and Cdx2 could limit colon cancer cell prolifer-
ation by inhibiting Wnt/β-catenin transcriptional activity [22,34,35].
Our findings, therefore, did not agree with the accepted description
of Cdx1. To directly test whether Cdx1 was an intestinal oncogene,
we carried out the present study.
Ectopic Expression of Cdx1 Had No Effect on Intestinal
Epithelial Architecture, Differentiation, or Proliferation
We generated three transgenic lines with robust transgene expres-
sion. Of importance for the interpretation of these results, Cdx1 was
both overexpressed and ectopically expressed. Thus, if Cdx1 had on-
cogenic properties in the intestinal epithelium, we would expect to
see intestinal polyps and cancers develop, as was seen when K-ras was
expressed in the intestine using a villin promoter [44]. However, no
spontaneous tumors or cancers were observed in our transgenic mice,
even in mice up to 24 months, nor was there any effect on prolifer-
ation in the crypt compartment. Together this is strong evidence that
Cdx1 does not act as classic oncogene in intestinal epithelial cells.
Figure 5. No change in crypt proliferation pattern due to ectopic
expression of Cdx1. (A) Immunohistochemistry with anti-BrdU an-
tibody shows that proliferating cells remain restricted to the crypts
in both 6-month-old wild-type and transgenic mice small intestine
and colon. (B) Quantification of epithelial proliferation based on
BrdU incorporation in the ileum and colon. BrdU-positive cells
per crypt were counted in 15 well-shaped crypts from three 6-
month-old mice for each founder. Matched wild-type littermates
were used as controls. Data for the combined analysis from all
three transgenic lines, from the ileum and colon (n = 9) are pre-
sented. Dark gray bar, wild-type mice; white bar, Villin–Cdx1 trans-
genic mice.
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Villin–Cdx1 Mice Had Reduced Adenoma Formation in a
Model for Colitis-Associated Cancer
As an additional test for Cdx1 oncogenic potential, we looked for
synergy between our transgene and a mouse model for colon cancer. If
Cdx1 possesses oncogenic properties in the colon, we would expect it
to enhance tumor production or growth in a mouse model for colon
carcinogenesis. We chose to use a combination of AOM with DSS
because it was an established model for inducible colon cancer in
Figure 6. Ectopic Cdx1 expression directed by the villin–Cdx1 transgene reduced the number of adenomas elicited by AOM/DSS treat-
ment. (A) Significant transgene expression demonstrated in rectum to squamo-columnar junction. Immunohistochemical staining for
Cdx1 (CPSP) and themyc-tagged transgene protein (anti-myc). (B) Combined analysis of both treatment groups. Black squares, wild-type
littermates receiving two rounds of 3% DSS; white squares, wild-type littermates receiving three rounds of 3% DSS; black circles, villin–
Cdx1 transgenic mice receiving two rounds of 3% DSS; white circles, villin–Cdx1 transgenic mice receiving three rounds of 3% DSS.
Statistical significance was determined by Student’s t test using a two-tailed distribution. (C) Subgroup analysis of treatment groups
using Student’s t test using a single-tailed distribution. TG, transgenic; WT, wild-type.
Table 1. Polyp Formation in Transgenic and Control Mice with AOM and DSS Treatment.
Villin–Cdx1 Nontransgenic Littermate
AOM and two rounds of 3% DSS 20 adenomas and 1 carcinoma in six mice (100% mice with polyps) 50 adenomas in six mice (100% mice with polyps)
AOM and two rounds of water 0 adenomas 0 adenomas
Vehicle and two rounds of 3% DSS 0 adenomas 0 adenomas
AOM and three rounds of 3% DSS 64 Adenomas in 11 mice (100% mice with polyps) 88 adenomas in nine mice (100% mice with polyps)
AOM and three rounds of water 0 adenomas 0 adenomas
Vehicle and three rounds of 3% DSS 0 adenomas 0 adenomas
Six-week-old villin–Cdx1 mice and nontransgenic littermate controls were given intraperitoneal injections of AOM (10 mg/kg) or vehicle. One week later, they received 3% DSS in their drinking water
for 7 days. Mice received one or two additional rounds of 3% DSS for 7 days. Fourteen weeks after the initial AOM injection, mice were sacrificed; the number of colonic polyps was scored and
adenomas were confirmed histologically.
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CD-1 mice [45]. CD-1 is an outbred strain of mice, which may ac-
count for the large variability in polyp numbers that we observed in
our study. Nonetheless, our findings were very significant. The trans-
genic mice had half as many rectal adenomas as their wild-type litter-
mates with this treatment. This difference was highly significant and
confirmed by statistical testing (P < .013). In addition, the polyps that
developed in the villin–Cdx1 mice tended to be physically smaller
than those in their nontransgenic littermates. These observations
are exactly the opposite of what would be expected from Cdx1 if it be-
haved as an oncogene in intestinal epithelium. In summary, whereas
this single study may be insufficient to designate Cdx1 as a tumor
suppressor in the intestinal epithelium, it is clear from this work that
Cdx1 does not behave as an oncogene in the intestinal epithelium.
Of great importance was the finding that Cdx1 expression, includ-
ing that of the Cdx1 transgene, was lost in the neoplastic polyps.
This confirms earlier observations that Cdx1 expression is lost in
most human and murine polyps and cancers [22,23,25,30]. This
finding was somewhat unexpected, as the transgene was expressed
under the control of a villin promoter, a gene whose expression is
often maintained colon cancers [46]. The endogenous villin gene re-
mained active and was expressed in all polyps, thus the loss of the
villin–Cdx1 transgene expression was specific to the transgene and
not due to a general loss of villin expression or a poorly differentiated
state of the neoplasm. It suggests that there must be a powerful ad-
vantage for neoplastic intestinal cells to lose their Cdx1 expression.
We do not yet know the mechanism by which the expression of
the transgene is silenced, whether by loss of heterozygosity, epigenetic
effects, or another mechanism. Whereas loss of endogenous Cdx1
gene expression in most colon cancers appears to be from epigenetic
silencing of the Cdx1 promoter [23–26], there are no reports in the
Figure 7. Expression of the transgene villin–Cdx1 transgene was lost in the adenomas elicited by AOM/DSS treatment. (A) Sections
were obtained from the AOM/DSS polyps and were immunohistochemically stained for Cdx1, the Myc-tagged Cdx1, or Cdx2 proteins.
A region of normal epithelium was included for comparison. (B) Staining for β-catenin and villin expression in the polyps from transgenic
mice. Insets: higher magnification photo of neoplastic cells.
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literature describing epigenetic regulation or loss of heterozygosity of
the villin gene. It is therefore not clear which mechanism is involved
here. Given that the villin–Cdx1 transgene consists of more than
12 Kb of mouse villin promoter and intronic sequence, inserted ran-
domly in the mouse genome, differentiating it from the endogenous
villin gene and determining the mechanism by which the transgene is
silenced would be a difficult task and is beyond the focus of this in-
vestigation into whether Cdx1 behaves in vivo as a classic oncogene.
It remains, however, an interest for future investigations. In conclu-
sion, these observations together strongly argue against an oncogenic
role for Cdx1 in intestinal carcinogenesis.
Cdx1 Expression Can Modulate Cdx2 Expression
in Murine Intestinal Epithelium
One unexpected finding was the reduction in Cdx2 expression not-
ed in the intestinal villi and colonic surface epithelium. Now, we do
not know if this is a direct or indirect effect by Cdx1 on the Cdx2
gene. Although there have been reports describing a regulatory effects
of Cdx1 or Cdx2 on Cdx1 gene expression [47], the reverse has not
been described. In transient transfection studies with human colon
cancer DLD1 cells, we have noted a reduction in CDX2 mRNA levels
when Cdx1 is expressed (data not shown). However, in studies with
two different murine Cdx2 promoter–luciferase reporter constructs,
including one with 8.8 kb of promoter sequence, Cdx1 expression
had no effect on Cdx2 promoter activity. Thus, this observation will
require additional experimentation to establish that Cdx1 regulates
Cdx2 expression. However, this remains an important observation,
because intestinal epithelial differentiation and gene expression pat-
terns were unaltered with the loss of Cdx2 protein. It suggests that
the ectopically expressed Cdx1 can compensate for Cdx2 and support
normal intestinal cell differentiation and gene expression. This obser-
vation therefore further undermines the hypothesis that Cdx1 and
Cdx2 have opposing effects on the intestinal epithelial proliferation
and differentiation and supports our hypothesis that these factors
share overlapping targets and functions.
One disappointment was that we did not see a reduction in intes-
tinal cell proliferation with Cdx1 overexpression. There are several po-
tential explanations for this. One possibility is that we did not get
enough Cdx1 overexpression in the proliferative crypt compartment.
Our immunohistochemical staining seems to support this possibility
(Figure 2), although other investigators using the same villin promoter
construct report significant transgene expression in crypt epithelial cells
[29]. Another possible explanation could be that the compensatory re-
duction in Cdx2 expression might have removed an important anti-
proliferative stimulus and, therefore, the Cdx1 transgene, whereas
substituting for the lost Cdx2 could not provide any additional anti-
proliferative effects. One final possibility is that, despite the in vitro
evidence to the contrary, Cdx1 has no antiproliferative effect on nor-
mal intestinal epithelial cells. We favor the first two explanations and
are considering future studies to address these concerns directly.
Tissue and Genetic Context of Expression Likely Explains
the Opposing Observations Regarding Cdx1 and Cdx2
in Carcinogenesis
Cdx1 and Cdx2 are potent transcription factors with a diverse ar-
ray of target genes and reported effects on proliferation and apoptosis
[7,8]. We believe the context in which the expression occurs defines
the cell’s response. In the context of normal intestinal epithelium,
where Cdx1 and Cdx2 expression occur naturally, these factors serve
to limit proliferation and promote differentiation and predominantly
act to inhibit tumorigenesis. However, in other contexts, including
other tissue contexts, the response to Cdx1 expression can be quite
different. When Cdx1 or Cdx2 are expressed in some nonintestinal
tissues, such as gastric epithelium or bone marrow stem cells, Cdx
expression may support carcinogenesis [17,48]. This may also be true
in intestinal cells lacking normal retinoblastoma function, either due
to experimental manipulations [49] or to natural occurrence, such as
colon cancer cells in which the retinoblastoma protein has been in-
activated by hyperphosphorylation. In summary, our observations
support the conclusion that the homeodomain transcription factor
Cdx1 is not an oncogene and does not have oncogenic properties
in the context of normal intestinal epithelium. Furthermore, overex-
pressed Cdx1 does not oppose Cdx2 actions in intestinal epithelium
but can instead substitute for Cdx2 when Cdx2 expression is lost.
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